On January 16, 2024 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, reported that it will participate in three upcoming investor conferences in January and February (Press release, Allogene, JAN 16, 2024, View Source [SID1234639266]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

B. Riley Oncology Conference
Thursday, January 18, 2024
12:30PM PT/3:30PM ET

Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Wednesday, February 7, 2024
8:30AM PT/11:30AM ET

Oppenheimer 34th Annual Healthcare Life Sciences Conference
Wednesday, February 14, 2024
9:00AM PT/12:00PM ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.